ATHLETES’ FOOT AFFECTS MORE THAN 9% OF PEOPLE Sydney, Australia – November 17, 2007 – A novel new oral treatment for Tinea, commonly known as Athletes’ Foot, is now being tested by Australian research teams in Melbourne, Sydney, Adelaide and Brisbane as part of a global study in the condition that affects over 9% of Australians. According... Read more
November 17th, 2007
Athletes, and non-athletes, between 18 and 65 wanted for tinea study
November 14th, 2007
Australian research teams test prawn shell treatment to combat hayfever
“DRUG FROM THE SEA” SHOWS POTENTIAL FOR ALLERGY SUFFERERS Sydney, Australia – November 14, 2007 – A novel agent for the treatment of rhinitis, commonly known as hayfever, is now being tested by Australian research teams in Melbourne, Sydney, and Brisbane. The agent is derived from the shells of marine crustaceans. Dr Rimmer from the... Read more
October 21st, 2007
Novotech in expansion mode as CRO sector continues to grow at 15%
BioPacificVentures and Co-Investor Capital Partners invest in Novotech and back expansion plans Sydney, Australia, Orange County, CA – October 21, 2007 — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, is now in rapid expansion mode as the CRO sector fundamentals continue to... Read more
July 1st, 2007
Novotech alerts Pharma and Biotechs at DIA 2007 to Australias new R&D tax break that applies to clinical trials
New Tax break comes into effect July 1, 2007 Atlanta, GA – July 1, 2007 — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, announced on the eve of DIA 2007 that the new tax breaks for research in Australia, which includes clinical trials, starts July 1, 2007. Novotech CEO Alek... Read more
May 15th, 2007
Novotech says Australia ideally placed to become Bioequivalence trials hub
Sydney, Australia, May 15, 2007 — Novotech, the largest independent Australian owned contract research organization (CRO) with expertise in TGA/EMEA/FDA registration said today Australia should aggressively market its bioequivalence trials capabilities overseas and take a large share of the multi-billion dollar sector. Already more than 70% of Novotech’s... Read more
May 8th, 2007
Updated checklist for CRO partnering and trials selection in Australasian region announced at BIO 2007
May 8, 2007 – Boston, MA — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, has released its updated “Clinical Trials Checklist” for CROs, biotech, pharma and even VCs, to assist in the often challenging task of selecting a clinical trials partner in the Australasian... Read more
